Summary of findings 2. Immunologic response to YF vaccine in HIV‐infected children vs. immunologic response to YF vaccine in HIV‐uninfected children.
| Immunologic response to YF vaccine in HIV‐infected children vs. immunologic response to YF vaccine in HIV‐uninfected children | ||||||
| Patient or population: Children with HIV infection Settings: Côte d’Ivoire Intervention: YF vaccine in HIV‐infected children vs.YF vaccine in HIV‐uninfected children | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Control | YF vaccine in HIV‐infected children vs.YF vaccine in HIV‐uninfected children | |||||
| Adequate antibody response (NT ≥1:10), follow‐up median 29 months | 737 per 1000 | 169 per 1000 (59 to 472) | RR 0.23 (0.08 to 0.64) | 75 (1 study) | ⊕⊝⊝⊝ very low1,2 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Pre‐antiretroviral era. 2 Very few participants. Grade down by 2.